It’s been a bad month for Pegasystems (NASDAQ: PEGA), with investors running for the exits after a huge top-line miss in Q3. For an enterprise software company, there’s probably nothing worse. Pegasystems sold off from all-time highs near $65 and now trades nearly 20% lower, in the low $50s.
Still, though, shares are up a good amount this year (see the YTD chart below), reflecting investors’ confidence in Pegasystems’ fundamental profile. Trading at just 4.5x EV/FY17 revenues, however, Pegasystem appears undervalued – especially as it’s one of the few enterprise software companies to post GAAP net earnings (GAAP earnings have doubled year to date), and as its operating cash flows have quadrupled.
PEGA data by YCharts
Top Undervalued Stocks To Watch Right Now: Endologix, Inc.(ELGX)
Advisors’ Opinion:
- [By Paul Ausick]
Endologix Inc. (NASDAQ: ELGX) dropped about 9.3% on Wednesday to post a new 52-week low of $4.78 against a 52-week high of $14.50 and a Tuesday close of $5.27. Volume of about 6 million was more than 3 times the daily average of around 1.7 million. The company on Tuesday announced a temporary shipping hold on its best-selling heart device, saying there was a manufacturing issue.
- [By Lisa Levin]
Endologix, Inc. (NASDAQ: ELGX) shares dropped 23 percent to $7.59 as the company issued an update on Nellix PMA process. Endologix disclosed that the FDA has requested the company to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System.
Top Undervalued Stocks To Watch Right Now: Inovio Pharmaceuticals, Inc.(INO)
Advisors’ Opinion:
- [By Lisa Levin]
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were also up, gaining 24 percent to $8.84 following announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response.
- [By Ben Levisohn]
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.
In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.
Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s DNA-based vaccine approach is safe and can rapidly transition to human studies.
Shares of Inovio Pharmaceuticalshave gained 4.3% to $9.24 at 2:50 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.3% to $284.29.
- [By William Patalon III]
In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.
- [By Keith Speights]
A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.
Top Undervalued Stocks To Watch Right Now: Vanguard Mega Cap Value ETF (MGV)
Advisors’ Opinion:
- [By Todd Shriber, ETF Professor]
Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).
